Unknown

Dataset Information

0

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.


ABSTRACT:

SUBMITTER: Eskelund CW 

PROVIDER: S-EPMC6278958 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4710541 | biostudies-literature
| S-EPMC6634960 | biostudies-literature
| S-EPMC10641095 | biostudies-literature
| S-EPMC7065472 | biostudies-literature
| S-EPMC10278520 | biostudies-literature
| S-EPMC6039666 | biostudies-literature
| S-EPMC7035866 | biostudies-literature
| S-EPMC7402838 | biostudies-literature
| S-EPMC7735159 | biostudies-literature
| S-EPMC7422137 | biostudies-literature